Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar 31;42(13):1228-1230.
doi: 10.1093/eurheartj/ehab092.

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial

Nikolaus Marx  1 , Jürgen Floege  2
Affiliations
Editorial

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial

Nikolaus Marx et al. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) or heart failure with reduced ejection fraction (HFrEF). CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HF, heart failure. *Data from DAPA-CKD  ,  . #Data from a meta-analysis from DAPA-HF and EMPEROR-Reduced.
See this image and copyright information in PMC

Comment on

References

    1. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662–1673. - PMC - PubMed
    1. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015;26:2504–2511. - PMC - PubMed
    1. Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695–725. - PubMed
    1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM; Board of the EURECA-m Working Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831–1843. - PubMed
    1. Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; for the DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis fromthe DAPA-CKD randomized controlled trial. Eur Heart J 2021;doi:10.1093/eurheartj/ehab094. - PubMed

MeSH terms